Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug
PTSM: Pharmaceutical Technology Sourcing and Management
Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.
Medicenna Therapeutics, a clinical stage immune-oncology company, has selected Kalon Biotherapeutics, an advanced biologics contract development and manufacturing company, to manufacture materials that will accelerate the development, testing, and Phase 3/commercialization of several new cancer drugs in the pipeline. The operations of Kalon Biotherapeutics are located in the National Center for Therapeutics Manufacturing on the campus of Texas A&M in College Station, Texas.
Kalon’s first project with Medicenna is for a clinical trial testing the effectiveness of Medicenna’s empowered cytokines (ECs) for children with brain cancer. The agreement provides for Kalon to manufacture the material that will be used in human clinical trials in children and adults with brain cancer.
Source: Kalon Biotherapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
